Basics Fate Therapeutics, Inc. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. IPO Date: October 1, 2013 Sector: Healthcare Industry: Biotech Market Cap: $124.58M Activated in VL: True Average Daily Range Avg Daily Range: $0.56 | 3.55% Avg Daily Range (30 D): $0.06 | 5.00% Avg Daily Range (90 D): $0.05 | 4.41% Institutional Daily Volume Avg Daily Volume: .89M Avg Daily Volume (30 D): 1.58M Avg Daily Volume (90 D): 1.72M Trade Size Avg Trade Size (Sh.): 113 Avg Trade Size (Sh.) (30 D): 285 Avg Trade Size (Sh.) (90 D): 300 Institutional Trades Total Inst.Trades: 3,463 Avg Inst. Trade: $2.74M Avg Inst. Trade (30 D): $1.11M Avg Inst. Trade (90 D): $.76M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.8M Avg Closing Trade (30 D): $1.27M Avg Closing Trade (90 D): $1.27M Avg Closing Volume: 204.27K     News Oct 26, 2025 @ 3:30 PM Fate Therapeutics Presents New Clinical Data at AC... Source: Fate Therapeutics May 28, 2025 @ 9:54 PM Fate Therapeutics Announces Phase 1 Data Presentat... Source: N/A Apr 2, 2025 @ 8:01 PM Fate Therapeutics Reports New Employee Inducement ... Source: N/A Feb 28, 2025 @ 6:00 PM NK Cell Therapy Market on Track for Exponential Gr... Source: Delveinsight Nov 29, 2024 @ 6:05 PM Fate Therapeutics Announces Leadership Transition Source: N/A Financials   TTM Q3 2025 Q2 2025 Basic EPS $-1.33 $-.27 $-.29 Diluted EPS $-1.33 $-.27 $-.29 Revenue $ 7.14M $ 1.74M $ 1.91M Gross Profit $ $ $ Net Income / Loss $ -156.09M $ -32.25M $ -34.07M Operating Income / Loss $ -174.73M $ -34.74M $ -36.97M Cost of Revenue $ $ $ Net Cash Flow $ 2.71M $ -.63M $ 5.19M PE Ratio